PDCD1 and hepatocellular carcinoma: Additionally, a phase 2 clinical trial has shown that camrelizumab (a PD-1 monoclonal antibody) combined with apatinib (a VEGFR-2 tyrosine kinase inhibitor) shows promising efficacy and acceptable safety in patients with advanced HCC in both the first-line and second-line settings (89).